Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Outlook Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
OTLK
Nasdaq
2836
www.outlooktherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Outlook Therapeutics, Inc.
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
- Feb 4th, 2025 2:05 pm
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
- Jan 31st, 2025 1:05 pm
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
- Jan 23rd, 2025 2:05 pm
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
- Jan 22nd, 2025 2:05 pm
Sector Update: Health Care Stocks Rise Late Afternoon
- Jan 16th, 2025 8:54 pm
Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD
- Jan 16th, 2025 5:44 pm
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
- Jan 16th, 2025 5:09 pm
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
- Jan 16th, 2025 11:00 am
Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss
- Dec 30th, 2024 12:45 pm
Outlook Therapeutics Reports 2024 Financial Results
- Dec 29th, 2024 3:50 am
Outlook Therapeutics provides ONS-5010/LYTENAVA update
- Dec 28th, 2024 1:10 pm
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
- Dec 27th, 2024 1:05 pm
Outlook Therapeutics® Streamlines Operations
- Dec 13th, 2024 9:30 pm
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
- Dec 4th, 2024 1:05 pm
Outlook Therapeutics® Announces Executive Leadership Transition
- Dec 3rd, 2024 9:30 pm
Outlook Therapeutics price target lowered to $9 from $50 at BTIG
- Nov 30th, 2024 10:50 am
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
- Nov 28th, 2024 3:29 pm
Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial
- Nov 27th, 2024 4:08 pm
Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial
- Nov 27th, 2024 4:07 pm
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
- Nov 27th, 2024 2:27 pm
Scroll